# BPC-157 TB-500 FAQ: the Wolverine blend, answered from the literature > BPC-157 TB-500 questions answered from the research record: mechanism, the actin pathway, synergy, dosage, safety, half-life, and regulatory status. Direct, cited, no guidance. The questions people actually ask about the Wolverine blend, with direct answers cited to the published literature — and the gaps marked as gaps. ## Mechanism and identity These BPC-157 TB-500 answers cover what each peptide is and how it works. ### How does TB-500 work (actin / Thymosin Beta-4)? TB-500 is the Ac-LKKTETQ fragment of Thymosin Beta-4; the LKKTETQ motif binds monomeric G-actin in a 1:1 complex, regulating the cytoskeletal dynamics that drive cell migration [3]. By sequestering the actin monomer and capping both ends, it controls the pool of actin available for filament assembly [3]. ### How does BPC-157 work compared to TB-500? BPC-157 supplies a cytoprotective and angiogenic signal through VEGFR2-Akt-eNOS [2], while TB-500 supplies an actin-sequestration and cell-migration signal [3]. They are described as complementary but largely non-overlapping pathways [4] — one acts on vessels and tissue protection, the other on the cytoskeleton. ### Do BPC-157 and TB-500 act through the same pathway? No. They act through complementary but largely non-overlapping pathways, which is the basis of the theoretical "synergy" claim — not a demonstrated combined mechanism [4]. BPC-157 signals via VEGFR2-Akt-eNOS [2]; TB-500 sequesters G-actin [3]. ### What does TB-500 stand for and how does it relate to Thymosin Beta-4? TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to residues 17-23, the actin-binding region, of the 43-residue protein Thymosin Beta-4 [7]. It is a fragment, which is why most "TB-500" efficacy data describe the full-length protein instead [4]. ### What is the Wolverine peptide blend? A research-community name for a two-peptide pairing of BPC-157 and TB-500, discussed as a tissue-repair "stack" [4]. It is not a single chemical entity and not an approved product; commercial vials carry a combined mass but no clinically validated ratio [4]. ### What is BPC-157 and TB-500? BPC-157 is a 15-amino-acid pentadecapeptide from a human gastric-juice protein [1]; TB-500 is the synthetic Ac-LKKTETQ fragment of Thymosin Beta-4 [7]. The blend pairs them as a tissue-repair stack. ## Combination, evidence, and efficacy These answers cover why the two are paired and what the evidence does — and does not — show. ### Why are BPC-157 and TB-500 combined (the Wolverine stack)? The rationale is complementary mechanisms: BPC-157's angiogenic and cytoprotective signal plus TB-500's cytoskeletal-migration signal [4]. This is a theoretical extrapolation from two separately characterized pathways, not a finding from a controlled combination study [8]. ### Is there any study showing BPC-157 and TB-500 work better together (synergy)? No. No peer-reviewed study defines a synergy ratio, dose, or endpoint for the two given together; the 2025 HSS Journal BPC-157 systematic review makes no mention of TB-500 or combination use [8]. ### Are there human clinical trials on the BPC-157 + TB-500 combination? No. There are no controlled clinical trials of the combination. Human data exist only for the individual constituents and are themselves thin — and for TB-500 are on full-length Thymosin Beta-4, not the 7-mer [4]. ### Does the BPC-157 TB-500 blend help tendon and ligament injuries? Animal studies of the individual peptides report improved tendon and ligament healing — for example, BPC-157 in the transected rat Achilles tendon [1] — but no combination study and no human efficacy data exist. ### Does BPC-157 and TB-500 help muscle tears and recovery? Preclinical rodent studies report muscle-repair effects for each peptide; thymosin beta-4 recruits myoblasts to injured muscle as a chemoattractant [6]. The combination's effect in humans is unproven. ### Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)? In preclinical models both do, by distinct routes: BPC-157 via VEGFR2-Akt-eNOS [2], and TB-500 / Thymosin Beta-4 via endothelial migration [4] — the shared vascular thread cited in the blend rationale. ### Does the BPC-157 TB-500 blend help wound healing? Animal models report wound-healing effects for the individual peptides, with thymosin beta-4 promoting cell migration and re-epithelialization [4]. No combination or human data exist for the blend. ### What is the latest research on BPC-157 and TB-500? Recent reviews (2024-2026) emphasize animal-model promise but scarce human safety data and no regulatory approval — a 2025 HSS Journal BPC-157 systematic review [8] and a 2026 Sports Medicine review of unapproved musculoskeletal peptides [9]. ## Dosage, pharmacokinetics, and handling These answers report what studies recorded, never a protocol for use. ### What is the half-life of BPC-157 and TB-500? BPC-157's elimination half-life was reported under 30 minutes in animal PK studies [2]; no validated human half-life exists for either constituent at research-use doses, and none for the blend [4]. ### How do you reconstitute a BPC-157 / TB-500 blend (10mg)? Both constituents are supplied as lyophilized powders, reconstituted in bacteriostatic or sterile water and refrigerated [4]. Product identity and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed. ### How often should you inject BPC-157 and TB-500? There is no validated dosing schedule for the blend [4]. Community "loading then maintenance" protocols have no controlled-trial basis and should not be treated as validated dosing. ### How do you cycle BPC-157 and TB-500? There is no validated cycling protocol [4]. Fixed-ratio vials and "loading" schedules circulating online have no basis in controlled human trials; the non-monotonic Tbeta4 dose-response undercuts "more is better" rationales [4]. ## Safety and regulatory status These answers cover the safety signals and the regulatory record. ### What are the side effects of BPC-157 and TB-500? The combination's safety is unproven [4]. A key theoretical concern is the pro-angiogenic and pro-migratory tumor signal associated with thymosin beta-4; BPC-157's long-term human safety is unknown [9]. No controlled human safety data exist for the pairing. ### Does TB-500 cause cancer or promote tumor growth? Thymosin beta-4 is implicated in tumor metastasis and angiogenesis; the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression [4]. This is a noted safety consideration, not an established human risk for the fragment. ### Is Wolverine legal? Neither BPC-157 nor TB-500 is an FDA-approved drug, and both are currently in FDA's 503A Category 2, restricting routine compounding access as the record stands [12]. Both are prohibited in sport by WADA. The full picture is on the [Wolverine legal status and 503A compounding access](/legal-status) page. ### Can you get BPC-157 from a compounding pharmacy? BPC-157 is currently in FDA's 503A Category 2 — identified as potentially presenting significant safety risks, effective with the September 29, 2023 list update — which is not within FDA's enforcement-discretion policy, restricting routine compounding access now [12]. It is also on the July 2026 PCAC agenda as a candidate under evaluation [14]. ### What is the FDA 503A status of Wolverine? Both constituents are currently in FDA's 503A Category 2 (effective September 29, 2023), and both are on the scheduled July 23-24, 2026 PCAC agenda as candidates "being considered for inclusion on the 503A Bulks List" — a discussion under evaluation, not a listing decision [12][14]. --- A pressed-herbarium reading room for the BPC-157 and TB-500 literature — two peptides mounted as specimens and cited to source, with no clinic behind the field-book and nothing here for sale.